Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for SGT-210 (Erlotinib) in Darier Disease, Skin disease/disorder. The expected timing is based on the latest available company guidance and may change.
Verification
Confirm timing and program details against the company announcement or filing.